---
run_id: halo-evidence-vs-diagnosis-validation-v10-generic-advice-prompted-03
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v10
benchmark_version: halo-evidence-vs-diagnosis-validation-v10-v1
model_condition: generic_advice_prompted
run_number: 3
model_name: gemma-4-31b-it-mlx:2
model_id: gemma-4-31b-it-mlx:2
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit; loaded_context_length 65536
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 65536
max_tokens: 1024
seed: 305
prompt_source: condition packet (generic_advice_prompted) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 61d771e2bff7fd2e18be1d2999d0f601760656e3e69b4622989ca7bffd3aff8e
source_packet: a short generic advice-quality request, then the frozen Advisor prompt; no rubric and no sources - see run-packet.md
source_packet_sha256: 372fe6128e2e633706cc66d44caf0e7dfaf2bba60181854165887aa7ed453ea9
condition_packet_sha256: 372fe6128e2e633706cc66d44caf0e7dfaf2bba60181854165887aa7ed453ea9
output_file: model-outputs/generic_advice_prompted-03.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - generic_advice_prompted (run 03)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v10-v1`, condition `generic_advice_prompted`, run 3 of 8. Real local-model run: `gemma-4-31b-it-mlx:2` via lmstudio, seed 305, on the frozen condition packet.

## Output

I recommend that you commit to the **Claim File Review**.

### Reasoning: The "Signal vs. Noise" Problem
Your current data is dangerously entangled. You have a "strong quarter," but it is being driven by two lagging indicators that mask product failure: **financial incentives** (bundle pricing) and **sales narratives** (roadmap promises).

The most alarming evidence is the behavioral pattern of your users:
1. **Managerial Vanity:** Usage is high, but it's coming from managers reviewing *closed* files. This means the tool is being used for auditing or reporting, not for active claim resolution.
2. **The "Novelty Drop":** Adjusters use it for two days and then quit. This is a classic sign of a tool that provides an initial "wow" factor but fails to integrate into the actual cognitive workflow.
3. **The Explainability Gap:** In health-liability, users abandon the tool because they cannot defend its output to reviewers. This is a fundamental product failure in a regulated industry; if an adjuster can't explain the "why," the tool is a liability, not an asset.

The Usage Quality Sprint (analytics) will only tell you *that* people are leaving; it won't tell you *why*. The Commercial Cleanroom (sales test) is too risky and late—you already have regional carriers planning to drop the feature. You cannot solve a value-proposition problem by tweaking the pricing model.

The **Claim File Review** is the only option that treats the product as a workflow tool rather than a sales metric. By seeing exactly where suggestions are overridden or rewritten, you move from "usage percentages" to "utility evidence." You will discover if DraftPath is actually helping resolve claims or if it's just generating "noise" that adjusters have learned to ignore.

### The Trade-offs
By choosing the Claim File Review, you are displacing the **Usage Quality Sprint**. You give up the ability to track real-time behavioral trends across the entire user base. You are trading *breadth* (quantitative dashboards) for *depth* (qualitative truth). If the problem is a simple UI friction point, you might miss it by focusing on file reviews; however, your current evidence suggests the problem is deeper—it's a lack of trust and explainability in the core logic.

### The Strongest Reason Against This Recommendation
The Claim File Review is slow, manual, and small-sample. It does not provide the "hard numbers" that CEOs and Boards typically crave during budget locks. While you are digging through files to find the truth, your competitors may be scaling "good enough" AI features faster. There is a risk that you spend the next quarter analyzing *why* it's broken while your sales team continues to sell a version of the product that doesn't exist, widening the gap between buyer expectation and user reality.

### Evidence That Would Change My Mind
I would pivot to the **Commercial Cleanroom** if you discovered that the "regional carrier" churn was an anomaly caused by a specific procurement quirk rather than product dissatisfaction. If you found that the "novelty drop" among adjusters was actually caused by a lack of permissions/access rather than a lack of utility, I would pivot to the **Usage Quality Sprint** to optimize the onboarding funnel. However, based on the "explainability" failure in health-liability, these are unlikely scenarios.
